Accelerated RadioTherapy of Squamous Cell carcinoma of the head And Neck - study II: preoperative accelerated versus postoperative conventional radiotherapy in patients with resectable cancer of the oral cavity

mea University Hospital (Sweden)0 个研究点目标入组 250 人开始时间: 2008年3月20日最近更新: 2022年4月25日

适应症

试验速览

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/34793864/ (added 13/04/2022)

•1. Over the age of 18 years, either sex
•2. Resectable (as classified before surgery with radical intent), histological proven, previously untreated, squamous cell carcinoma of all grades and stages in the oral cavity without distant metastases. All T3-T4 and/or N2-3 tumours of the oral cavity can be included. Additionally T1-T2 and any N tumours of the oral cavity can be included provided the tumour is invading at clinical/radiological examination.
•3. The tumour has to be judged as accessible for primary radical surgery and the patient must be expected to withstand combined surgery and radiotherapy
•4. The patient must be able to understand the information about the treatment and give a written informed consent to participate in the trial

•1. Previous anti-tumour treatment within three months before treatment
•2. Evidence of distant metastases beyond the regional nodes in the neck
•3. Co-existing disease prejudicing survival will exclude the patient (expected survival greater that six months)
•4. Previous malignant disease in the head and neck region will exclude the patient with exception for basal cell carcinoma or curatively treated squamous cell carcinoma of the skin with follow-up time of at least three years
•5. Adequate follow-up study must be possible; this will exclude a patient who is uncooperative

发起方

mea University Hospital (Sweden)